|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy显示文摘 | Luca Arcaini Michele Merli Stefano Volpetti Sara Rattotti Manuel Gotti Francesco Zaja Jürg Schifferli | 2012 | Clinical and Developmental Immunology2012，，： | 1 |
| 2 | Distinctive Clinical and Histological Features of Waldenstr?m’s Macroglobulinemia and Splenic Marginal Zone Lymphoma显示文摘 | Luca Arcaini Marzia Varettoni Emanuela Boveri Ester Orlandi Sara Rattotti Silvia Zibellini Michele Merli Marco Lucioni Silvia Rizzi Manuel Gotti Lucia Morello Cristiana Pascutto Marco Paulli | 2011 | Clinical Lymphoma Myeloma and Leukemia2011，，1： | 1 |
| 3 | High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma显示文摘 | Francesca Novara Luca Arcaini Michele Merli Francesco Passamonti Silvia Zibellini Silvia Rizzi Sara Rattotti Elisa Rumi Cristiana Pascutto Annalisa Vetro Cesare Astori Emanuela Boveri Marco Lucioni Marco Paulli Orsetta Zuffardi Mario Lazzarino | 2009 | Human Pathology2009，，11： | 1 |
| 4 | Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi显示文摘 | Luigi Rigacci Umberto Vitolo Luca Nassi Francesco Merli Andrea Gallamini Patrizia Pregno Isabel Alvarez Flavia Salvi Rosaria Sancetta Antonio Castagnoli Annibale Versari Alberto Biggi Michele Gregianin Ettore Pelosi Teodoro Chisesi Alberto Bosi Alessandro | 2007 | Annals of Hematology2007，，： | 1 |
| 5 | 自体骨与脱蛋白牛骨基质在严重上颌骨萎缩行同期上颌窦侧壁开窗提升术中的应用:随机对照试验显示文摘目的:在随机对照优效性试验中比较100%脱蛋白牛骨基质(deproteinised bovine bone matrix.DBBM)移植(试验组)和100%自体骨(autogenous bone.AB)移植(平行对照组)的差异。材料与方法:对上颔实底剩余牙槽骨高度在1~3mm的患者进行上颌窦提升术,随机分为两组.分别植入DBBM和AB,并且同期植入种植体。随机化是由计算机分配并用信封密封,影像学检查人员对于分组不知情。术后8个月安装愈合基台并且在术后9个月安装临时修复体。观察的结果变量有种植体失败、修复体失败、并发症、椅旁时间、术后疼痛和负重6个月后的放射线评估骨量变化。结果:共40名患者随机分为两组:DBBM组20名(32颗种植体).AB组20名(27颗种植体)。AB组1名患者失访。DBBM组有2颗种植体失败.而AB组无种植体失败(P=0.4872)。所有计划安装的修复体都顺利实施。DBBM组有1例出现并发症.AB组有2例(P=0.6050)。DBBM组的椅旁时间更短.能缩短大约27.3min(P=0.0428)。采用视觉模拟评分法(VAS)测量术后6d的疼痛差异.发现DBBM组比AB组有0.2的差异.疼痛更轻(P=0.6838)。垂直骨量的差异为0.0mm(95%CI-1.1,1.1;P=0.9703);边缘骨吸收的差异在AB组更明显.为0.3mm(95%Cl-03,0.9:P=0.3220)。结论:在上颌寞提升同期行种植体植入时比较DBBM和AB移植的差异.发现除了椅旁时间外其余均无差异。 | Mauro Merli Marco Moscatelli Giorgia Mariotti Roberto Rotundo Michele Nieri 刘长营 李钧 | 2015 | 中国口腔医学继续教育杂志2015，0，6： | 1 |
| 6 | Myelofibrosis: Prognostication and cytoreductive treatment显示文摘Myeloproliferative neoplasms include three diseases: polycythemia vera, essential thrombocythemia and primary myelofibrosis(PMF), currently diagnosed according to the 2008 World Health Organization criteria. Patients with PMF may encounter many complications, and, among these, disease progression is the most severe. Concerning prognostication of Myelofibrosis(MF), the International Prognostic scoring system(IPSS)(International Prognostic Scoring System) model at diagnosis and the Dynamic IPSS(DIPSS) anytime during the course of the disease may be useful to define survival of MF patients. The IPSS and the DIPSS are based on age greater than 65 years, presence of constitutional symptoms, hemoglobin level less than 10 g/d L, leukocyte count greater than 25 × 109/L, and circulating blast cells 1% or greater. Cytogenetic profile and mutational analysis seem to be the next step to implement MF prognostication. Concerning treatments, hydroxyurea has been considered until now the drug of choice when an anti-myeloproliferative effect is needed, but recent data on JAK inhibitors demonstrated a significant effect of these drugs on splenomegaly and symptoms. | Margherita Maffioli Domenica Caramazza Barbara Mora Michele Merli Francesco Passamonti | 2014 | World Journal of Hematology2014，3，3： | 0 |
| 7 | Rituximab maintenance in follicular lymphoma patients显示文摘Rituximab maintenance(RM)therapy following successful induction has recently emerged as a highly effective treatment for follicular lymphoma(FL).Randomized trials analyzing the impact of RM compared to observation alone have demonstrated a significantly better outcome in terms of progression-free survival(but not overall survival)in patients(pts)who received as first-line treatment single-agent rituximab,standard chemotherapy(CVP)and recently also immunochemotherapy(R-CHOP,R-CVP or R-FND),as shown by preliminary results of the PRIMA trial.Also in the setting of relapsed disease,RM has shown significant benefit either after chemotherapy or immunochemotherapy.RM has been generally well tolerated,and treated pts developed only mild toxicity,mainly a small increased rate of neutropenia,hypogammaglobulinaemia and self-limiting upper-respiratory tract infections.Moreover,no cumulative or unexpected toxicities were observed and quality of life was not affected.These data have established RM therapy as an important part of multi-modal therapeutic strategies in patients affected by FL. | Luca Arcaini Michele Merli | 2011 | World Journal of Clinical Oncology2011，2，7： | 0 |
| 8 | Wafer技术:一种骨重建的新方法显示文摘本研究介绍了基于引导骨组织再生技术与三维骨增量onlay植骨技术的一种新技术。这个技术分为两阶段:首先用自体皮质骨板与胶原膜形成屏障,再用该屏障将包括脱蛋白牛骨基质、自体血液与口内移植骨在内的混合物加以包裹。五位患者接受了该技术的治疗。术后6个月,可观察到平均骨体积增大值为1062mm'。平均最大线性增量为3.65mm。对再生区域进行组织学检查,可见有新生密质骨的形成,并不伴有炎症征象。共计13颗种植体被植入.所有患者均对效果表示满意,且未观察到并发症出现。 | Mauro Merli Marco Moscatelli Giorgia Mariotti Alessandro Motroni Annalisa Mazzoni Simona Mazzoni Lorenzo Breschi Michele Nier 李嫣斐(译) 张新春(审) | 2020 | 中国口腔医学继续教育杂志2020，23，2： | 0 |
| 9 | Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma显示文摘The association of hepatitis C virus(HCV) and B-cell non-Hodgkin lymphomas(NHL) has been highlighted by several epidemiological and biological insights; however the most convincing evidence is represented by interventional studies demonstrating the capability of antiviral treatment(AT) with interferon(IFN) with or without ribavirin to induce the regression of indolent lymphomas, especially of marginal-zone origin. In the largest published retrospective study(100 patients) the overall response rate(ORR) after first-line IFN-based AT was 77%(44% complete responses) and responses were sustainable(median duration of response 33 mo). These results were confirmed by a recent metaanalysis on 254 patients, demonstrating an ORR of 73%. Moreover this analysis confirmed the highly significant correlation between the achievement of viral eradication sustained virological response(SVR) and hematological responses. Two large prospective studies demonstrated that AT is associated with improved survival and argue in favor of current guidelines' recommendation of AT as preferential first-line option in asymptomatic patients with HCV-associated indolent NHL. The recently approved direct-acting antiviral agents(DAAs) revolutionized the treatment of HCV infection, leading to SVR approaching 100% in all genotypes. Very preliminary data of IFN-free DAAs therapy in indolent HCV-positive NHL seem to confirm their activity in inducing lymphoma regression. | Michele Merli Giuseppe Carli Luca Arcaini Carlo Visco | 2016 | World Journal of Gastroenterology2016，22，38： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员